HIFU FOR BREAST CANCER
AND THYROID NODULES
Ultrasound-guided HIFU destroys small breast tumours and symptomatic thyroid nodules without incisions, general anaesthesia, or hospital admission β offering a non-surgical alternative for carefully selected patients across both indications.
analyticsAt a Glance
- check_circleBreast HIFU: complete pathological ablation in 65β87% of tumours β€2 cm under ultrasound guidance
- check_circleThyroid HIFU: volume reduction of 50β70% at 12 months for benign nodules; CE-marked systems in clinical use
- check_circleBoth indications performed under local anaesthesia or conscious sedation β outpatient same-day discharge
- check_circleAvailable at specialist HIFU centres in China with extensive experience in both breast and thyroid applications
Why HIFU Is Used for Breast Tumours and Thyroid Nodules
Breast surgery β even minimal lumpectomy β requires general anaesthesia, operating theatre time, and visible scarring. Thyroid nodule surgery requires general anaesthesia, neck incision, and carries risks of recurrent laryngeal nerve injury and hypoparathyroidism. HIFU provides a single-visit, anaesthesia-free, scar-free alternative for patients where the lesion is small, ultrasound-visible, and amenable to focal thermal ablation.
βFor a 78-year-old woman with a 1.5 cm breast cancer who cannot tolerate general anaesthesia β HIFU under local anaesthesia offers treatment she could not otherwise safely receive.β
Breast Cancer: Inoperable and Elderly Patients
USgHIFU is validated for small (β€2 cm), ultrasound-visible, unifocal invasive breast carcinoma in patients who are poor surgical candidates due to age, comorbidity, or patient preference. Complete pathological ablation rates of 65β87% are reported for tumours β€2 cm with adequate sonographic visibility.
Thyroid Nodules: Surgery-Avoiding Ablation
HIFU is CE-marked and widely used in Europe and China for benign thyroid nodules causing compressive symptoms (dysphagia, neck pressure) or cosmetic concern. A single treatment session reduces nodule volume by 50β70% at 12 months β eliminating symptoms in the majority without surgery, voice changes, or calcium loss.
Key Clinical Numbers
Published data for both indications from prospective series and registry studies.
- 65β87%Complete breast tumour ablation rate (β€2 cm)Reported across Chinese USgHIFU series and the HIFU breast cancer registry β highest rates for solid, well-defined, hypovascular tumours.
- 50β70%Thyroid nodule volume reduction at 12 monthsConsistent across European and Chinese benign thyroid nodule HIFU series; symptom relief in 80β90% of patients with compressive nodules.
- <1%Recurrent laryngeal nerve injury rate (thyroid HIFU)Substantially lower than thyroid surgery (2β5% for temporary; 0.5β1% permanent) β the key quality-of-life advantage for thyroid HIFU.
- 1 visitTypical treatment sessions requiredSingle-session treatment for most small breast tumours and thyroid nodules β the entire procedure is completed in 30β90 minutes.
Eligibility Criteria for Breast Cancer HIFU
The following criteria reflect the patient selection framework used in published breast HIFU trials and Chinese institutional protocols.
| Criterion | Suitable for HIFU | Less Suitable / Contraindicated |
|---|---|---|
| Tumour size | β€2 cm (strict); up to 3 cm in selected cases | Tumours >3 cm β incomplete ablation risk high |
| Tumour type | Invasive ductal carcinoma (IDC); fibroadenoma | ILC and tumours with EIC β poor acoustic reflectivity; underestimates true extent |
| Ultrasound visibility | Well-defined hypoechoic mass on B-mode ultrasound β required | Isoechoic or poorly defined tumours β targeting accuracy insufficient |
| Distance from skin/chest wall | >1 cm from both skin surface and chest wall | <1 cm from skin β burn risk; <1 cm from chest wall β intercostal nerve/lung risk |
| Nodal status | cN0 on imaging β no clinical nodal disease | Clinical nodal disease β systemic and nodal treatment needed beyond focal ablation |
| Tumour to skin distance | β₯1 cm | <1 cm β surface cooling inadequate; skin burn reported in early series |
| Prior breast surgery | No prior surgery at same site preferred | Prior surgery β scar tissue causes acoustic shadowing and aberrant heating |
Thyroid Nodule HIFU: What Happens
Thyroid HIFU is performed with the patient lying supine, neck extended, under local anaesthesia or light sedation β entirely as an outpatient procedure.
- 1
Pre-Procedure Ultrasound and Mapping
High-resolution thyroid ultrasound confirms nodule dimensions, vascularity, echogenicity, and its distance from the recurrent laryngeal nerve (posterior margin), trachea, and carotid artery.
- 2
Patient Positioning
Patient lies supine with neck hyperextended over a bolster. Acoustic coupling gel is applied to the neck. The transducer is positioned against the skin over the nodule.
- 3
Local Anaesthesia or Sedation
Local lidocaine infiltration around the nodule is standard for most systems. Light IV sedation (midazolam) is added at patient preference. General anaesthesia is not required.
- 4
HIFU Ablation
The HIFU system (Echopulse or SONICTAC) delivers sequential focal sonications across the nodule volume. Real-time ultrasound monitoring shows the developing hyperechoic ablation zone. Each sonication lasts 3β5 seconds.
- 5
Immediate Post-Treatment Check
Contrast-enhanced ultrasound confirms the non-perfused ablated volume. Vocal cord mobility is assessed by indirect laryngoscopy before the patient leaves β a standard safety check for recurrent laryngeal nerve function.
- 6
Discharge
Patients are discharged 1β2 hours after the procedure on mild analgesics. Mild neck soreness for 24β48 hours is expected. Follow-up ultrasound at 1 month and 6 months tracks nodule regression.
HIFU vs Surgery for Thyroid Nodules
For benign thyroid nodules causing symptoms, HIFU and surgery achieve comparable symptom relief through different risk profiles.
HIFU
- No general anaesthesia requiredLocal anaesthesia only β suitable for patients with cardiovascular, respiratory, or other comorbidities that elevate surgical anaesthetic risk.
- No permanent neck scarA single invisible coupling gel contact β no surgical incision, no scar visible at the neckline.
- Thyroid function preservedHIFU ablates the nodule only β the surrounding thyroid parenchyma remains intact and functioning; no hypothyroidism from the procedure itself.
- Recurrent laryngeal nerve risk <1%Substantially lower than surgical risk (2β5% temporary, 0.5% permanent) β critical for patients whose occupation depends on voice quality.
Thyroid Surgery (Hemithyroidectomy)
- Definitive histological diagnosisSurgical excision provides a complete histological specimen β excluding malignancy with certainty. HIFU requires pre-procedure biopsy to confirm benign pathology.
- Complete nodule removalSurgery physically removes the nodule β HIFU achieves 50β70% volume reduction at 12 months; some residual nodule tissue typically remains.
- Better for very large or suspicious nodulesNodules >4 cm or with any concerning ultrasound features (microcalcifications, irregular margins) should not be treated with HIFU β surgical excision remains the standard.
- More established long-term dataLong-term thyroid HIFU data (>5 years) are limited compared to the decades of surgical outcome data β important for younger patients with multi-decade follow-up implications.
More from the HIFU Therapy Resource Library
Continue exploring HIFU β from the foundational science to other oncological applications and technology platforms.
- HIFU Therapy β Complete Treatment Guide
- What Is HIFU? Non-Invasive Focused Ultrasound Explained
- HIFU for Uterine Fibroids: MRgFUS Complete Guide
- HIFU for Prostate Cancer: Whole-Gland and Focal Treatment
- HIFU for Pancreatic Cancer: Pain Relief and Local Control
- HIFU Technology Platforms: HAIFU, JC, and MRI-Guided Systems
Frequently Asked Questions
Common questions from patients exploring HIFU for breast or thyroid conditions.
Breast and Thyroid HIFU Questions
Can HIFU treat malignant thyroid cancer?
HIFU's approved indication for thyroid disease is benign nodules β not thyroid cancer. Differentiated thyroid cancers (papillary and follicular) are treated with thyroidectomy, often with radioiodine, as these cancers require complete gland removal and lymph node staging. HIFU cannot address regional lymph node disease or provide the definitive histological clearance that surgery achieves. If your nodule has been biopsied and shows malignancy (including low-risk papillary microcarcinoma), the management decision should be made with an endocrinologist and a thyroid surgeon, not substituted with HIFU.
Will my breast cancer come back after HIFU ablation?
Local recurrence after breast HIFU ablation is possible β particularly if the ablation was incomplete or if residual tumour at the margin was not fully covered. The local recurrence rates in published series for tumours β€2 cm with complete ablation (confirmed by post-procedure imaging and, in some series, excision biopsy) are broadly comparable to lumpectomy. However, HIFU does not address multifocal disease, nodal staging, or systemic micrometastatic disease β adjuvant endocrine therapy, chemotherapy, and radiotherapy recommendations from your oncologist apply equally whether your local treatment was surgery or HIFU.
How soon can I return to normal activity after thyroid HIFU?
Most patients return to desk-based work within 24β48 hours of thyroid HIFU. Mild neck soreness, difficulty swallowing, and a sensation of neck tightness are common for 2β5 days and resolve spontaneously. Strenuous neck exercise and heavy lifting are avoided for 1 week. Vocal changes (temporary hoarseness) occur in approximately 2β5% of patients and typically resolve within 2β4 weeks as the ablated tissue resorbs and swelling reduces. Persistent voice change beyond 4 weeks should prompt early assessment by the treating team.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Explore HIFU for Your Breast or Thyroid Condition
CancerFax reviews your ultrasound, biopsy pathology, and clinical history to assess whether HIFU is appropriate for your breast tumour or thyroid nodule β and connects you with experienced specialist centres in China and India.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist or endocrinologist before making treatment decisions.